Oncopeptides AB (publ) (STO:ONCO)
1.622
-0.078 (-4.59%)
At close: Mar 2, 2026
Oncopeptides AB Employees
Oncopeptides AB had 75 employees as of December 31, 2025. The number of employees decreased by 5 or -6.25% compared to the previous year.
Employees
75
Change
-5
Growth
-6.25%
Revenue / Employee
948.24K SEK
Profits / Employee
-3.33M SEK
Market Cap
463.60M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75 | -5 | -6.25% |
| Sep 30, 2025 | 75 | -4 | -5.06% |
| Jun 30, 2025 | 75 | 8 | 11.94% |
| Mar 31, 2025 | 75 | 13 | 20.97% |
| Dec 31, 2024 | 80 | 23 | 40.35% |
| Sep 30, 2024 | 79 | 15 | 23.05% |
| Jun 30, 2024 | 67 | 4 | 6.35% |
| Mar 31, 2024 | 62 | 3 | 5.08% |
| Dec 31, 2023 | 57 | 16 | 39.02% |
| Sep 30, 2023 | 64 | 24 | 60.50% |
| Jun 30, 2023 | 63 | 19 | 43.18% |
| Mar 31, 2023 | 59 | -17 | -22.37% |
| Dec 31, 2022 | 41 | -121 | -74.69% |
| Sep 30, 2022 | 40 | -281 | -87.54% |
| Jun 30, 2022 | 44 | -269 | -85.94% |
| Mar 31, 2022 | 76 | -218 | -74.15% |
| Dec 31, 2021 | 162 | -118 | -42.14% |
| Sep 30, 2021 | 321 | 89 | 38.36% |
| Jun 30, 2021 | 313 | 159 | 103.25% |
| Mar 31, 2021 | 294 | 173 | 142.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Works Technologies AB | 29 |
| Mendus AB | 20 |
| Corline Biomedical AB | 13 |
| Xintela AB | 13 |
| Ascelia Pharma AB | 11 |
| AlzeCure Pharma AB | 11 |
| Medivir AB | 10 |
| Infant Bacterial Therapeutics AB | 8 |
Oncopeptides AB News
- 5 days ago - Oncopeptides AB (publ) 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 11 days ago - Oncopeptides AB (STU:OND) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ... - GuruFocus
- 11 days ago - Q4 2025 Oncopeptides AB Earnings Call Transcript - GuruFocus
- 11 days ago - Oncopeptides AB (publ) (ONPPF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Oncopeptides AB (publ) (ONPPF) Q4 2025 Sales/ Trading Statement Call - Slideshow - Seeking Alpha
- 6 weeks ago - Oncopeptides AB (publ) (ONPPF) Q4 2025 Sales/Trading Call Transcript - Seeking Alpha
- 3 months ago - Oncopeptides AB (FRA:OND) Q3 2025 Earnings Call Highlights: Strong Sales Growth Amid Strategic ... - GuruFocus
- 3 months ago - Q3 2025 Oncopeptides AB Earnings Call Transcript - GuruFocus